Association Between Aldosterone and Hypertension Among Patients With Overt and Subclinical Hypercortisolism

Abstract Introduction Hypertension is one of the most common clinical features of patients with overt and subclinical hypercortisolism. Although previous studies have shown the coexistence of autonomous cortisol and aldosterone secretion, it is unclear whether aldosterone plays a role in hypertension among patients with hypercortisolism. Therefore, we examined the associations of plasma aldosterone concentrations (PACs) with hypertension among patients with overt and subclinical hypercortisolism. Methods This single-center retrospective cohort study included patients with adrenal tumor and serum cortisol levels after 1-mg dexamethasone suppression test >1.8 µg/dL (50 nmol/L). Using multivariable regression models adjusting for baseline characteristics, we investigated the association of PACs with systolic blood pressure and postoperative improvement of hypertension after the adrenalectomy. Results Among 89 patients enrolled in this study (median age, 51 years), 21 showed clinical signs of Cushing syndrome (overt hypercortisolism) and 68 did not show clinical presentations (subclinical hypercortisolism). We found that higher PACs were significantly associated with elevated systolic blood pressure among patients with subclinical hypercortisolism (adjusted difference [95% CI] = +0.59 [0.19-0.99], P = 0.008) but not among those with overt hypercortisolism. Among 33 patients with subclinical hypercortisolism and hypertension who underwent adrenalectomy, the postoperative improvement of hypertension was significantly associated with higher PACs at baseline (adjusted risk difference [95% CI] = +1.45% [0.35-2.55], P = 0.01). Conclusion These findings indicate that aldosterone may contribute to hypertension among patients with subclinical hypercortisolism. Further multi-institutional and population-based studies are required to validate our findings and examine the clinical effectiveness of the intervention targeting aldosterone for such patients.

[1]  M. Omura,et al.  Cortisol Co-Secretion and Clinical Usefulness of ACTH Stimulation Test in Primary Aldosteronism: A Systematic Review and Biases in Epidemiological Studies , 2021, Frontiers in Endocrinology.

[2]  H. Sasano,et al.  Precise Mapping of Intra-Adrenal Aldosterone Activities Provides a Novel Surgical Strategy for Primary Aldosteronism , 2020, Hypertension.

[3]  K. Watson,et al.  Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium , 2020, Hypertension.

[4]  M. Infante,et al.  Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging , 2019, Front. Endocrinol..

[5]  F. Ceccato,et al.  The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome , 2019, Front. Endocrinol..

[6]  H. Sasano,et al.  Aldosterone Suppression by Dexamethasone in Patients With KCNJ5-Mutated Aldosterone-Producing Adenoma , 2018, The Journal of clinical endocrinology and metabolism.

[7]  J. Spence,et al.  The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension , 2018, Annals of Internal Medicine.

[8]  Tomoaki Tanaka,et al.  New diagnostic criteria of adrenal subclinical Cushing's syndrome: opinion from the Japan Endocrine Society. , 2018, Endocrine journal.

[9]  H. Sasano,et al.  Evaluation of Cortisol Production in Aldosterone-Producing Adenoma , 2017, Hormone and Metabolic Research.

[10]  M. Omura,et al.  KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma , 2017, Journal of hypertension.

[11]  J. Funder.  Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology , 2017, International journal of molecular sciences.

[12]  Michael Biehl,et al.  Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism , 2017, JCI insight.

[13]  F. Veglio,et al.  Guidelines for primary aldosteronism: uptake by primary care physicians in Europe , 2016, Journal of hypertension.

[14]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[15]  Martin Reincke,et al.  Subclinical hypercortisolism: a state, a syndrome, or a disease? , 2015, European journal of endocrinology.

[16]  H. Sasano,et al.  Adrenal CYP11B1/2 expression in primary aldosteronism: Immunohistochemical analysis using novel monoclonal antibodies , 2014, Molecular and Cellular Endocrinology.

[17]  T. Suda,et al.  Evaluation of the diagnostic criteria for Cushing’s disease in Japan [Review] , 2013 .

[18]  H. Sasano,et al.  Primary aldosteronism associated with subclinical Cushing syndrome , 2012, Journal of Endocrinological Investigation.

[19]  Katsutoshi Takahashi,et al.  Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. , 2011, Endocrine journal.

[20]  M. Anlauf,et al.  Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. , 2011, European journal of endocrinology.

[21]  L. Hamm,et al.  Pivotal Role of the Kidney in Hypertension , 2010, The American journal of the medical sciences.

[22]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[23]  Y. Cheung.  A modified least-squares regression approach to the estimation of risk difference. , 2007, American journal of epidemiology.

[24]  H. Sasano,et al.  Clinical Characteristics of Aldosterone-Producing Microadenoma, Macroadenoma, and Idiopathic Hyperaldosteronism in 93 Patients with Primary Aldosteronism , 2006, Hypertension Research.

[25]  T. MacDonald,et al.  Review of aldosterone- and angiotensin II-induced target organ damage and prevention. , 2004, Cardiovascular research.

[26]  H. Sasano,et al.  Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. , 2002, Metabolism: clinical and experimental.

[27]  J. Whitworth,et al.  Cushing, cortisol, and cardiovascular disease. , 2000, Hypertension.

[28]  J. Connell,et al.  Cortisol effects on body mass, blood pressure, and cholesterol in the general population. , 1999, Hypertension.

[29]  T. Kotchen,et al.  Hypertension and aldosterone overproduction without renin suppression in Cushing's syndrome from an adrenal adenoma. , 1979, The American journal of medicine.

[30]  I. Komiya,et al.  Concurrent hypersecretion of aldosterone and cortisol from the adrenal cortical adenoma. , 1979, The American journal of medicine.

[31]  M. Litwin,et al.  Guidelines for the Management of Hypertension , 2015 .

[32]  Yutaka Imai,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) , 2014, Hypertension Research.

[33]  K. Shimamoto.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 (JSH2014) , 2014 .

[34]  Iacopo.  Diagnosis and Treatment of Subclinical Hypercortisolism , 2011 .

[35]  T. Yoshimoto,et al.  Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome. , 2011, Endocrine journal.

[36]  Yong Liu,et al.  Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. , 2009, Cardiovascular research.

[37]  G. Albertin,et al.  Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. , 2002, The Journal of clinical endocrinology and metabolism.